Cellular Goods Share Discussion Threads

[n0rbie] 08/11/2021 16:25

Reason for today's rise other than a bit of volume and rampers out in force?

[kirk 6] 08/11/2021 16:12

Going to go mental tomorrow any slight dip being bought up. I will be very supervised if this didn't close above 10p tomorrow

[ccr1958] 08/11/2021 15:04

Good buying at 8.20. Tick up coming ..

[amelio] 08/11/2021 14:25

That would be the preferred move but I expect a close above 8p will attract a few looking for the breakout.Last time we saw this volume spike it sustained a rise for a number of days. 10p likely to be taken out fairly quickly imo.

[fantasticsaga1] 08/11/2021 13:19

Really nice rise here today. Let's hope this rises slowly as opposed to big spikes and retraces. This is starting to look good.

[amelio] 08/11/2021 12:33

Something brewing here, been a month since the last director purchase which was a sizeable chunk

[scotty666] 08/11/2021 12:22

8p has some resistance then should get going again - hopefully over 10p pre launched

[datait] 08/11/2021 11:46

Ready catapult up and beyond

[kirk 6] 08/11/2021 10:43

Yep this is just the very beginning of the start of the rise for cellular goods. Especially given celebrities own stock here we could see the biggest mkp here

[oapknob1] 08/11/2021 10:29

Hopefully they have enough product to meet demand on initial launch. One tweet from a certain celebrity global brand influencer, who is also an investor in CBX, could send demand through the roof.

[ccr1958] 08/11/2021 09:48

Yes good start to the week

[amelio] 08/11/2021 09:16

Nice volume this morning, potential about breakout from its 7p consolidation zone

[oapknob1] 05/11/2021 22:31

Would be nice

[kirk 6] 05/11/2021 15:52

20p next week

[david gruen] 05/11/2021 15:40

Not long now.

[oapknob1] 05/11/2021 11:40

Tiny trades trying to peg this. How long can they hold it down ?

[kirk 6] 04/11/2021 09:55

Yep Q1 2022 will potentially be transformational for the share price

[ashleyjv] 04/11/2021 09:01

I've doubled my holding this week and planning on a few more during the course of this month, want to get in before it all kicks off in December

[oapknob1] 04/11/2021 08:14

Quiet BB considering product launch due next month. Still accumulating ?
900000 warrants for share options.

[kirk 6] 28/10/2021 10:05

https://www.edisongroup.com/cbd-2021/This is big

[ashleyjv] 19/10/2021 11:13

Not much going on until December. I'm planning a top up myself but not just yet

[amelio] 19/10/2021 11:02

Nice quiet board, worth reminding myself of the 2m share purchase @7.75p by the CE just 2 weeks ago. Buying today at a 10% discount a no brainer imo.

[sharetalk] 13/10/2021 09:15

Check out fellow CBD company Chill Brands Group (CHLL) which already has products on the market and the recent comment from Viridian Capital about potentially building Chill into one of the largest brands in the world:

Twitter @ChillCBD
12/10/2021

"This is an opportunity to build one of the largest brands in the world," said Viridian Capital Advisors Founder and CEO Scott Greiper speaking after the company's annual general meeting. "That's why I'm here."

Welcome to #TeamChill Mr. Greiper! Glad to have you as captain!

[whites123] 11/10/2021 08:27

Here is the OCTP RNS..

But, also due this week are the results and also as we enter week 8 since the USA announcement then we can also expect to see mention of the shares trading OTC.. :-)
WITHOUT any fund raising.. :-)

Trading at some 40% below IPO with BIG HITTERS like Imperial Brands as main shareholders then expect good things..

Oxford Cannabinoid
New Partnerships Targeting Trigeminal Neuralgia

RNS Number : 5760O
Oxford Cannabinoid Tech.Holdings
11 October 2021





Oxford Cannabinoid Technologies Holdings plc



New Partnerships Targeting Trigeminal Neuralgia



Accelerated focus on chronic pain relief underpinned by new service agreements



· Extension of pain management portfolio - initially targeting trigeminal neuralgia

· Strengthened relationships with key industry providers

· Focus on reducing time and cost to market



Oxford Cannabinoid Technologies Holdings plc ("OCTP" or the "Company"), the holding company of Oxford Cannabinoid Technologies Ltd ("OCT")(together, the "Group"), a pharmaceutical company developing prescription cannabinoid medicines for approval by key medicines regulatory agencies worldwide and targeting the US$ multi-billion pain market, announces the signing of new partnerships to target trigeminal neuralgia ("TN") - an increasingly prevalent chronic pain condition.



TN, which is also known as tic douloureux, is a chronic pain condition that affects the trigeminal nerve producing an excruciating, stabbing, electric shock-like pain. A patient may experience up to 100 attacks per day, with a constant throbbing, aching or burning sensation between attacks. About 150,000 new cases of TN are diagnosed each year, and in 2021 there were over 65,000 cases in the UK.



With current treatments only partially effective and with adverse side-effects, OCT aims to provide a drug-device combination product for sufferers and has signed a number of service agreements to accelerate development.



The Group's TN product concept is a combination of unnamed phytocannabinoids (pCBs) that will be administered to the lungs using a simple metered dose inhaler. Administration to the lungs should reduce onset time and the extensive first-pass metabolism associated with oral administration of cannabinoids.



The Group aims to obtain Orphan Drug Designation (ODD) which will allow OCTP to retain market exclusivity through regulatory protections, and may reduce time and cost to market. The programme is designed for an accelerated route to first-time-in-human (FTiH) with Phase 1 clinical trials planned for Q3 2022.



Supply Agreements



Purisys

A new supply agreement with Purisys LLC ("Purisys")(Athens, GA, USA) secures ultra-high purity, cannabinoid active pharmaceutical ingredients ("APIs") for the current preclinical drug development and future clinical and commercial supplies for the Group's Programme 2. Purisys has an industry-leading track record of more than a decade producing cannabinoid APIs under commercial drug master files (DMFs) that have been successfully referenced in registered pharmaceutical marketing applications. Purisys operates in full compliance with global regulatory pharmaceutical standards and utilizes its DMFs as well as extensive regulatory experience to aid pharmaceutical companies in gaining regulatory approval of new and improved therapies to treat, cure, or prevent disease.



Oz-UK Ltd

In addition, OCTP has entered into a commercial agreement with Oz-UK Ltd, Corsham, UK, for the development of a cannabinoid metered dose inhaler formulation, which will include studies aiming to identify and define the excipient/formulation components, as well as the selection of the canister, valve, and actuator. The selected formulation and device aim to deliver high-purity cannabinoids through the inhalation route which will allow faster and more efficient absorption of the APIs intended to provide both short and long term relief from neuralgias.



Voisin Consulting Life Sciences ("VCLS")

In order to enable the development and regulatory strategy of the Group's combination product, it has entered a further work package under the agreement with VCLS previously announced on 1 June 2021. VCLS is a global leader in supporting pharmaceutical, biotech and medtech partners in expediting access of healthtech products to regulated markets. VCLS will provide support to define nonclinical risk and gap analysis, regulatory strategy and roadmap, as well as clinical development strategy.



Dr John Lucas, Chief Executive Officer of OCTP, said: "We are delighted to have further expanded our portfolio. The pain caused by TN can be extremely debilitating and we are looking forward to working towards a pain management solution with our partners. We remain focused on developing our portfolio and increasing our growth potential as we progress our drug development programmes through preclinical and clinical trials. "